Skip to main content
Premium Trial:

Request an Annual Quote

Thomas Schweins

Premium

Qiagen said this week that it has named Thomas Schweins as its vice president of corporate strategy.

The newly created position, said the company, involves developing, implementing, and monitoring Qiagen’s long-term strategy and market development activities. Schweins will also be responsible for defining the company’s licensing and acquisition strategy, while coordinating and monitoring the firm’s application portfolio.

According to Qiagen, Schweins most recently was with the German branch of The Boston Consulting Group, were he was manager and core team member of the pharma/healthcare and corporate development practice areas.

Prior to this, he was technology manager and assistant to the board at Hoechst/Aventis. Schweins holds a PhD from the Max-Planck-Society and a MSc from the University of Southern California, Los Angeles.

The Scan

Rise of BA.5

The New York Times reports that the Omicron subvariant BA.5 has become the dominant version of SARS-CoV-2 in the US.

UK Health Secretary Resigns

Sajid Javid, the UK health secretary, resigned along with Chancellor Rishi Sunak, saying they cannot work with Prime Minister Boris Johnson's government, CNN reports.

Clones From Freeze-Dried Cells

A team in Japan has cloned mice from freeze-dried skin cells, according to the Guardian.

Genome Research Papers on Craniosynostosis, Macaque Retrotransposition, More

In Genome Research this week: structural variants in craniosynostosis, LINE-1 activity in rhesus macaque brain, and more.